Immunogenicity, Efficacy, and Safety of Biosimilar Insulin Glargine (Gan & Lee Glargine) Compared With Originator Insulin Glargine (Lantus) in Patients With Type 1 Diabetes After 26 Weeks Treatment
Titel:
Immunogenicity, Efficacy, and Safety of Biosimilar Insulin Glargine (Gan & Lee Glargine) Compared With Originator Insulin Glargine (Lantus) in Patients With Type 1 Diabetes After 26 Weeks Treatment
Auteur:
Christofides, Elena A. Stankiewicz, Andrzej Denham, Douglas Bellido, Diego Franek, Edward Nakhle, Samer Łukaszewicz, Monika Reed, John Cózar-León, Victoria Kosch, Christine Karaś, Piotr Fitz-Patrick, David Handelsman, Yehuda Warren, Mark Hollander, Priscilla Huffman, David Raskin, Philip Oroszlán, Tamás Lillestol, Michael Ovalle, Fernando